J 2022

Synthesis of C-prenylated analogues of stilbenoid methyl ethers and their cyclic dihydrobenzopyranyl derivatives as potential anti-inflammatory agents

PÍŽOVÁ, Hana, Milan MALANÍK, Karel ŠMEJKAL, Michal ORAVEC, Pavel BOBÁĽ et. al.

Basic information

Original name

Synthesis of C-prenylated analogues of stilbenoid methyl ethers and their cyclic dihydrobenzopyranyl derivatives as potential anti-inflammatory agents

Authors

PÍŽOVÁ, Hana (203 Czech Republic, belonging to the institution), Milan MALANÍK (203 Czech Republic, belonging to the institution), Karel ŠMEJKAL (203 Czech Republic, belonging to the institution), Michal ORAVEC and Pavel BOBÁĽ (703 Slovakia, guarantor, belonging to the institution)

Edition

RSC Advances, Cambridge, Royal Society of Chemistry, 2022, 2046-2069

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.900

RIV identification code

RIV/00216224:14160/22:00126331

Organization unit

Faculty of Pharmacy

UT WoS

000769020900001

Keywords in English

NATURAL STILBENOIDSVITIS-VINIFERAIN-VITRORESVERATROLDEMETHYLATIONINHIBITORSARYL

Tags

Tags

International impact, Reviewed
Změněno: 14/9/2022 08:37, JUDr. Sabina Krejčiříková

Abstract

V originále

An efficient and versatile synthesis of the naturally occurring C-prenylated stilbenoid methyl ethers and their synthetic analogues is presented. The synthesis represents a six step convergent process including an optimised C-prenylation method. Furthermore, during the demethylation process, six new dihydro-benzopyranyl derivatives were obtained and isolated.

Links

GF21-38204L, research and development project
Name: Komplexy vybraných přechodných kovů s rostlinnými látkami s anti-NF-kappa B a pro-PPAR duální aktivitou
Investor: Czech Science Foundation, Partner Agency (Austria)
MUNI/A/1682/2020, interní kód MU
Name: Návrh, syntéza a hodnocení derivátů skupin léčiv s inhibiční enzymatickou aktivitou
Investor: Masaryk University